Trials / Unknown
UnknownNCT04979585
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
Camrelizumab Combined With Anlotinib and Nab-paclitaxel in Patients With Untreated Advanced Mucosal Melanoma:a Single-arm, Multicenter, Open-label Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Di Wu · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the objective response rate of camrelizumab combined with anlotinib and nab-paclitaxel in patients with untreated advanced mucosal melanoma.
Detailed description
The current traditional cytotoxic single agent or combination chemotherapy cannot clearly improve the overall survival rate of patients with advanced melanoma.From the current point of view, combination therapy will be one of the inevitable trends in the future development of tumor immunotherapy. So carry out this research To evaluate the objective response rate of camrelizumab combined with anlotinib hydrochloride and albumin paclitaxel in the first-line treatment of patients with advanced mucosal melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | 200mg ,IV,d1,Q3W. |
| DRUG | Anlotinib | 8mg,oral, d1-14,Q3W. |
| DRUG | nab-Paclitaxel | 260mg/m2,IV,d1,Q3W. |
Timeline
- Start date
- 2021-07-15
- Primary completion
- 2023-04-14
- Completion
- 2023-08-14
- First posted
- 2021-07-28
- Last updated
- 2021-08-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04979585. Inclusion in this directory is not an endorsement.